The recent funding round brings Naveris’ total capital raised to $51 million. The financing will be used to advance the commercialization of Naveris’ blood test tools for the early detection of cancers caused by human papillomavirus, according to the Sept. 19 Naveris news release.
The funding round was led by Gurnet Point Capital, with participation from TechU Ventures and the venture capital arm of the American Cancer Society, BrightEdge.
